3+ Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Ana Amicarella of EthosEnergy, John Arnold of Centaurus Capital, Chris George of Octopus Electric Vehicles, and the 2024 Houston Innovation Awards judges. Photos courtesy

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes an energy leader, an electric vehicle expert, and more.

Ana Amicarella, CEO of EthosEnergy

Ana Amicarella, CEO of EthosEnergy, joins the Houston Innovators Podcast to discuss the company's growth amid the energy transition. Photo courtesy of EthosEnergy

For most of her career, Ana Amicarella has been the only person in the room who looks like her. But as CEO of Houston-based EthosEnergy, she's changing that.

"The energy sector for sure is highly dominated by men, but I think it's such an exciting environment," Amicarella says on the Houston Innovators Podcast. "What I try to do at every job that I go to is I try to increase representation — diverse representation and females in the company. And I measure that when I started and when I end. I want to be able to make a difference."

Amicarella joined EthosEnergy — which provides rotating equipment services and solutions to the power, oil and gas, and industrial markets — as CEO in 2019 a few years after it was in 2014 as a joint venture between John Wood Group PLC and Siemens Energy AG. Prior to her current role, she served in leadership roles at Aggreko an GE Oil and Gas. Read more.

John Arnold, founder of Centaurus Capital

A Houston company has raised funding from a local investor. Photo via Centaurus Capital

A Houston company has closed its series B extension at $25 million.

MetOx International, which develops and manufactures high-temperature superconducting (HTS) wire, announced it closed a $25 million series B extension. Houston-based Centaurus Capital, an energy-focused family office, and New System Ventures, a climate and energy transition-focused venture firm, led the round with participation from other investors.

"MetOx has developed a robust and highly scalable operation, and we are thrilled to partner with the Company as it enters this pivotal growth stage," says John Arnold, founder of Centaurus, in a news release. "The market for HTS is expanding at an unprecedented pace, with demand for HTS far outweighing supply. MetOx is poised to be the leading U.S. HTS producer, closing the supply gap and bringing dramatic capacity to high power innovations and applications. Their progress and potential are unmatched in the field, and we are proud to support their growth." Read more.

Chris George, United States co-lead at Octopus Electric Vehicles

Texas is positioned to be a great state for the EV industry, writes this expert. Photo via LinkedIn

As Texans continue to invest in electric vehicles, public charging needs to be able to meet an increased demand, according to Chris George, the United States co-lead at Octopus Electric Vehicles, who wrote a guest column for InnovationMap about the state's potential when it comes to EVs.

"As we look to the future of transport and energy, the synergy between NEVI and Tesla’s network should create a compelling narrative for those thinking about leasing an EV," he writes. "Combine that with exciting new battery tech and potential range improvements, fueled by West Texas wind and solar, Texas is positioned to be a great state for the EV industry." Read more.

2024 Houston Innovation Awards judges

Here's who's calling the shots for the 2024 Houston Innovation Awards. Photos courtesy

Ten Houstonians are in the hot seat for deciding the best companies and individuals in Houston's innovation ecosystem.

InnovationMap has announced its 2024 Houston Innovation Awards judging panel, which includes startup founders, nonprofit leaders, investors, corporate innovators, and more. In addition to the 10 judges, InnovationMap Editor Natalie Harms will serve as the editorial representative on the judging panel.

The selected judges will evaluate applications from the nearly 300 nominations that were submitted this year. The judges will be using their expertise to evaluate the nominees' applications, which are due to InnovationMap this week. Read more.

Ana Amicarella, CEO of EthosEnergy, joins the Houston Innovators Podcast to discuss the company's growth amid the energy transition. Photo courtesy of EthosEnergy

How this Houston business leader is promoting diversity, nimbleness amid energy transition

Houston innovators podcast episode 254

For most of her career, Ana Amicarella has been the only person in the room who looks like her. But as CEO of Houston-based EthosEnergy, she's changing that.

"The energy sector for sure is highly dominated by men, but I think it's such an exciting environment," Amicarella says on the Houston Innovators Podcast. "What I try to do at every job that I go to is I try to increase representation — diverse representation and females in the company. And I measure that when I started and when I end. I want to be able to make a difference."

Amicarella joined EthosEnergy — which provides rotating equipment services and solutions to the power, oil and gas, and industrial markets — as CEO in 2019 a few years after it was in 2014 as a joint venture between John Wood Group PLC and Siemens Energy AG. Prior to her current role, she served in leadership roles at Aggreko an GE Oil and Gas.

Recently, EthosEnergy announced it's being acquired by New York private equity firm, One Equity Partners, which Amicarella says is very interested in investing into EthosEnergy and its ability to contribute to the energy transition.

"What One Equity Partners will bring is tremendous decisiveness. They won't delay in deciding what is good for the company — I've already seen examples," Amicarella says, adding that the deal hasn't get been finalized. "They are going to make decisions and trust the management team, I think our pace of change will be enormous compared to what it used to be."

While EthosEnergy has customers from traditional oil and gas, she says she leads the company with the energy transition at the top of her mind, and that means being able to grow and evolve.

"One of the behaviors we look to have at EthosEnergy is an ability to be nimble," Amicarella says, "because we know market conditions change. Think of all the things we've had to go through in the last five years."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston researchers develop dissolvable implant for targeted cancer drug delivery

cancer research

Researchers at Houston Methodist have developed a biodegradable implant that can be used to safely and consistently deliver drug treatments to tumors and then dissolve without the need for further surgery.

The implant is only the size of a grain of rice, but its potential is staggering. The biodegradable nanofibrous drug-eluting seed (b-NDES) works as a reservoir parked inside a soft tumor, where it can slowly release immune-stimulating drugs over time. This overcomes a consistent problem with drugs such as immune checkpoint inhibitors. Normal systemic administration sees comparatively little of the drug making its way to the tumor, with most of it circulating throughout the body. The b-NDES is like deploying a small guerrilla fighting force embedded in enemy territory, doing maximum damage to the entrenched tumor.

"To improve cancer treatment, we're trying to start a fire inside the tumor itself," Corrine Chua, associate professor in the Center for BioNanoengineering at Houston Methodist Research Institute, said in a news release. "By activating immune cells directly within the tumor microenvironment, those cells can then travel throughout the body and seek out cancer wherever it exists. The b-NDES platform was developed to help keep therapeutic drugs concentrated inside tumors while minimizing exposure to healthy tissues.”

Chua co-led the study with Alessandro Grattoni, chair and director of the Center for BioNanoengineering at Houston Methodist Research Institute.

The study included support from the Nancy Owens Breast Cancer Foundation and the National Institutes of Health/National Cancer Institute.

Chau and Grattoni used preclinical models of triple-negative breast cancer, an aggressive form of cancer that is estrogen receptor-negative, progesterone receptor-negative and HER2-negative. Because of the receptor negativity, some popular treatments like tamoxifen and trastuzumab are ineffective. Chemotherapy has been shown to be the best course of action.

The b-NDES implant is deployed alongside radiation drugs. It keeps the drugs focused on the tumor, reducing the amount of harmful side effects typically seen when drugs are circulated more widely in the body. In 60 percent of the models, tumors were eliminated and did not cause side effects beyond the tumor site. Once the drugs have been deployed, the implant breaks down naturally.

While promising, more research will have to be done to expand use to other tumor types.

"Although the study focused on triple-negative breast cancer models, the approach could have broader applications for solid tumors," Grattoni added in the release. "It could potentially be used in cancers where there is a tumor lesion accessible for placement, including pancreatic or lung cancers."

New Houston platform Same Day Reels launches for on-demand content creation

In The Moment

If an event doesn't happen on Instagram, did it even really happen? In today's social media-driven age of branding and audience engagement, the answer increasingly is no.

Houston entrepreneur Karen De Amat is looking to fill the online content creation needs of companies with her new venture, Same Day Reels, which launched in early August. It will serve as a platform to connect companies and brands with talent that can help turn an event into a viral moment as it is happening.

"Events move quickly, and social media moves even faster,” said De Amat. “Same Day Reels was built to help brands capture the moment while it still matters. We are creating a more efficient way for businesses and creators to work together. Brands need content faster, and creators need more opportunities to turn their talent into real work. Same Day Reels brings those needs together.”

The company is focused on adding livestreams and concurrent short video content to "activations, launches, fundraisers, grand openings, conferences, hospitality experiences, and private celebrations." Such content can significantly increase the visibility of a product or brand according to digital marketing brands like Wyzowl, whose data found 63 percent of people in 2026 prefer to learn about new products via short video.

Packages offered by Same Day Reels will include filming, editing, and publishing content within hours of the targeted event.

De Amat says that her content creation platform will be a way to preserve the excitement of events and launches by enshrining them with immediate social media-driven memories.

“Event content is no longer just something you post after the fact,” De Amat said. “It is part of how people experience, remember and share the moment.”

Previously, De Amat is also the founder and CEO of Social Behavior, an influencer marketing company she launched from her home in 2014. It quickly garnered an array of clients and thrust De Amat into the spotlight, including numerous appearances on Fox 26's The Isiah Factor. Influencer Marketing Hub named her one of the top CEOs of influencer marketing companies in Houston in 2025.

---

This article originally appeared on CultureMap.com.

Bristol Myers Squibb to build $2.3B Houston pharma manufacturing campus

coming soon

New Jersey-based pharmaceutical giant Bristol Myers Squibb Co. has officially named Houston as the home of its new state-of-the-art manufacturing site.

The 60,000-square-foot facility represents a $2.3 billion investment, according to a news release. It is expected to create 500 skilled jobs and will be located in Houston's Generation Park.

BMS first announced that it was considering Houston among 16 other cities for the facility in May. The new hub will manufacture small molecule, biologic and antibody-drug conjugates and is part of a $40 billion commitment to invest in the United States over five years. Construction is slated to begin next year, with the facility coming online in 2030.

"We're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life," Christopher Boerner, CEO and board chair of BMS, said in the release.

The new facility will feature a modular, multi-modal design, which will allow the company to reconfigure and add to its manufacturing capabilities over time. BMS says it expects the facility to "(grow) in scale and capability well beyond its opening configuration."

"Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region’s ability to support a world-class, digitally advanced supply operation,” Karin Shanahan, EVP and chief supply chain and operations officer of BMS, added in the release. “This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities. It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands.”

Texas Gov. Greg Abbott shared that the state has granted BMS a $4.89 million Texas Enterprise Fund (TEF) grant for the project. TEF grants, administered by the Texas Economic Development & Tourism Office, support business relocation or expansion projects that create "new, good-paying jobs in the community and attract significant new capital investment to the state." The development is also a qualified project under the Texas Jobs, Energy, Technology, and Innovation (JETI) program.

“Texas is a global hub for life sciences, where today’s innovations shape the future of healthcare,” Abbott said in a news release. “This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities. With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers.”

"Bristol Myers Squibb’s announcement is a tremendous win for Texas and the Houston region, further reinforcing our position as a premier destination for life sciences and advanced manufacturing,” added Greater Houston Partnership President and CEO Steve Kean.

Last fall, Eli Lilly and Co. selected Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston, for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.

View All Listings